成年人视频一区二区_国产成人调教视频在线观看_亚洲毛片专区_特别特别黄的网站在线观看免费_亚洲毛片儿免费观看_打扑克又痛又叫软件_欧美99久久精品乱码影视_国内自拍偷拍青青草

E

COMPANY PROFILE

?

Pioneering a First-in-Class Drug Discovery Engine in China for Global.

Pioneering a First-in-Class Drug Discovery Engine in China for Global.

Mission
Build an innovation-driven discovery engine to identify value-creating opportunities and transform cutting-edge science into FIC/BIC assets to address unmet medical needs through MNC partnerships or NewCo/Spinoff formation.
Strategy
With a strong network in China and worldwide including clinical cohort studies, identify clinically relevant new targets/mechanisms, provide early validation, early de-risk, and deliver high quality assets/newcos with sustainable growth potential.
Investment Return
Will be achieved by delivery of high quality PCC molecules and early clinical POC through MNC partnerships, out-licensing opportunities and formation of Spinoffs or NewCos.
  • 1.An Early De-risk EngineA FIC-focused biotech company with an early de-risk wet-lab capabilities, leveraging fast-growing innovations from China and worldwide.
  • 2.FIC Discovery TeamAn MNC-trained experienced FIC discovery team covering disease biology, med chem, antibody/nanobody, PK/PD, and in vivo pharmacology.
  • 3.Strong NetworkAccess to nationwide top universities and research hospitals, especially in clinical resources enabling new target/mechanism ID as well as effective clinical POC.
  • 4.Core CapabilitiesEnabling key technology platforms including SBDD, AIDD, PROTAC/TPD, DAC/XDC, organoids, and tissue-targeting.
  • 5.FundingsSupported by global VC funds and strategic partnerships.
Mission
Build an innovation-driven discovery engine to identify value-creating opportunities and transform cutting-edge science into FIC/BIC assets to address unmet medical needs through MNC partnerships or NewCo/Spinoff formation.
Strategy
With a strong network in China and worldwide including clinical cohort studies, identify clinically relevant new targets/mechanisms, provide early validation, early de-risk, and deliver high quality assets/newcos with sustainable growth potential.
Investment Return
Will be achieved by delivery of high quality PCC molecules and early clinical POC through MNC partnerships, out-licensing opportunities and formation of Spinoffs or NewCos.

LEADERSHIP TEAM

?

Bei Shan, Ph.D.

Co-Founder & CEO

A well-recognized leader in pharmaceutical R&D with>20 years of management experience in pharma/biotech industry(Tularik,Amgen,Lilly). Inventor of 37 patents granted by the US Patent Office, including Amgen's PCSK9 antibody for the treatment of cardiovascular disease (Rapatha?).

Bai Lu Ph.D.

Co-Founder

World-renowned neuroscientist; major contribution in neurotrophin research. NIH Director's Award, Ray Wu Award, Mathilde Solowey Award, and Thomson Reuters' World's Highly Cited Researcher, Elsevier's "Most-cited scientists in China".Leadership positions: NIH, GSK, Tsinghua

Leping Li, Ph.D.

Chemistry

30 years of experience in drug discovery. He has directly led multi-disciplinary teams, including drug discovery and preclinical drug development, pharmaceutical research (CMC), drug substance and drug product manufacturing, and quality assurance. 

Zheng Huang, Ph.D.

Biology

30 years of pharmaceutical R&D experience, with broad expertise in inflammatory, immunological, metabolic and cardiovascular diseases. Contributor to 4 launched drugs (Singulair?, Arcoxia?, Vioxx?, Tredaptive?).

JOIN US

?

Our headquarters in Beijing is based in a newly constructed >4000m2 facility equipped with state-of-the-art chemistry and biology laboratory instruments, located in Zhongguancun Beilun Industrial Park, Haidian District.

JOB OPENINGS